
    
      The purpose of this monocenter, single-arm, phase I trial is to determine the
      maximum-tolerated-dose, dose-limiting toxicity (DLT) and preliminary efficacy and safety of
      RAD001 in combination with Mitomycin C in patients with advanced gastric cancer.
    
  